Compare FCF & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCF | ALMR |
|---|---|---|
| Founded | 1934 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 1994 | 2026 |
| Metric | FCF | ALMR |
|---|---|---|
| Price | $20.29 | $25.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | $24.07 | ★ $35.40 |
| AVG Volume (30 Days) | ★ 1.0M | 704.4K |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.77% | N/A |
| EPS Growth | ★ 5.76 | N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.49 | $59.79 |
| Revenue Next Year | $5.68 | $39.75 |
| P/E Ratio | $24.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.00 | $21.58 |
| 52 Week High | $22.34 | $39.61 |
| Indicator | FCF | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 41.09 |
| Support Level | $19.85 | $23.69 |
| Resistance Level | $20.87 | $29.06 |
| Average True Range (ATR) | 0.33 | 3.14 |
| MACD | 0.01 | -0.75 |
| Stochastic Oscillator | 67.38 | 14.55 |
First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.